Comparison of cardioprotective efficacy of two thromboxane A2 receptor antagonists

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 3, 2003, Pages 481-488

  Ge, Zhi Dong ^a   Auchampach, John A ^a   Piper, Galen M ^a   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Hydroxyl radicals; Ischemia; KT2 962 TXA2 receptor antagonist; Reperfusion

Indexed keywords

6 ISOPROPYL 3 [4 (4 CHLOROBENZENESULFONYLAMINO)BUTYL]AZULENE 1 SULFONIC ACID; DALTROBAN; HYDROXYL RADICAL; KT2 962; MYELOPEROXIDASE; RADIOACTIVE MICROSPHERE; SCAVENGER; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL USE; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART VENTRICLE FIBRILLATION; HEMODYNAMICS; INCIDENCE; MEAN ARTERIAL PRESSURE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPERFUSION INJURY;

ANIMALS; BENZENESULFONATES; CARDIOTONIC AGENTS; CYCLOHEPTANES; DOGS; MYOCARDIAL REPERFUSION INJURY; PHENYLACETATES; RECEPTORS, THROMBOXANE; SULFONAMIDES;

EID: 0037369542     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200303000-00018     Document Type: Article

References (44)

1. Kuzuya T, Hoshida S, Nishida M, et al. Increased production of arachidonate metabolites in an occlusion-reperfusion model of canine myocardial infarction. Cardiovasc Res. 1987;21:551-8.
2. 2 in acute myocardial infarction. Am Heart J. 1984;108:868-72.
3. 2 balance and on the atherogenic index in myocardial ischemia in dogs. Biomed Biochim Acta. 1988;47:S149-52.
4. Tada M, Kuzuya T, Hoshida S, et al. Arachidonate metabolism in myocardial ischemia and reperfusion. J Mol Cell Cardiol. 1988;20(suppl 2):135-43.
5. Smith EF III, Lefer AM, Smith JB. Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Can J Physiol Pharmacol. 1980;58:294-300.
6. 2 release during coronary occlusion and reperfusion in anaesthetised dogs. Cardiovasc Res. 1982;16:99-106.
7. 2-induced aggregation of human platelets. Circulation. 1986;73:847-54.
8. 2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs. Circ Res. 1990;66:596-607.
9. 2. Exp Mol Pathol. 1979;30:449-57.
10. 2 analog. Prostaglandins. 1981;21:443-56.
11. 2/prostaglandin H2 binding sites in guinea pig cardiac membrane preparations. J Mol Cell Cardiol. 1994;26:915-23.
12. Schror K, Thiemermann C. Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177). Br J Pharmacol 1986;87:631-7.
13. Nichols WW, Mehta J, Wargovich TJ, et al. Reduced myocardial neutrophil accumulation and infarct size following thromboxane synthetase inhibitor or receptor antagonist. Angiology. 1989;40:209-21.
14. Bhat AM, Sacks H, Osborne JA, et al. Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats. Am Heart J 1989;117:799-803.
15. Brezinski ME, Yanagisawa A, Lefer AM. Cardioprotective actions of specific thromboxane receptor antagonist in acute myocardial ischemia. J Cardiovasc Pharmacol 1987;9:65-71.
16. Brezinski ME, Yanagisawa A, Darius H, et al. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats. Am Heart J. 1985;110:1161-7.
17. Singh J, Seth SD, Manchanda SC, et al. Protective actions of a thromboxane receptor antagonist, SQ 29548 on the ischemic myocardium: morphologic and hemodynamic effects. Prostaglandins Leukot Essent Fatty Acids. 1997;56:105-10.
18. Smith EF III, Earl CQ, Egan JW. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion. Prostaglandins Leukot Essent Fatty Acids. 1989;38:15-23.
19. Golino P, Ambrosio G, Villari B, et al. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion. J Am Coll Cardiol. 1993;21:493-501.
20. Engelman DT, Watanabe M, Engelman RM, et al. Hypoxic preconditioning preserves antioxidant reserve in the working rat heart. Cardiovasc Res. 1995;29:133-40.
21. Das DK, Maulik N, Moraru II. Gene expression in acute myocardial stress. Induction by hypoxia, ischemia, reperfusion, hyperthermia and oxidative stress. J Mol Cell Cardiol. 1995;27:181-93.
22. Bolli R, Jeroudi MO, Patel BS, et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res. 1989;65:607-22.
23. Powell SR, Hall D. Use of salicylate as a probe for OH formation in isolated ischemic rat hearts. Free Radic Biol Med. 1990;9:133-41.
24. Liu P, Hock CE, Nagele R, et al. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemia-reperfusion injury in rats. Am J Physiol. 1997;272(5 part 2):H2327-36.
25. Merrill G, McConnell P, Vandyke K, et al. Coronary and myocardial effects of acetaminophen: protection during ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2001;280:H2631-8.
26. McHugh NA, Merrill GF, Powell SR. Estrogen diminishes postischemic hydroxyl radical production. Am J Physiol. 1998;274:H1950-4.
27. Merrill GF. Acetaminophen and low-flow myocardial ischemia: efficacy and antioxidant mechanisms. Am J Physiol Heart Circ Physiol. 2002;282:H1341-9.
28. Yoshida T, Maulik N, Engelman RM, et al. Targeted disruption of the mouse Sod I gene makes the hearts vulnerable to ischemic reperfusion injury. Circ Res. 2000;86:264-9.
29. Auchampach JA, Pieper GM, Cavero I, et al. Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol. 1998;93:361-71.
30. + exchange inhibition-induced cardioprotection in dogs: effects on neutrophils versus cardiomyocytes. Am J Physiol Heart Circ Physiol. 2000;279:H1563-70.
31. Gross GJ, Auchampach JA. Role of ATP dependent potassium channels in myocardial ischaemia. Cardiovasc Res. 1992;26:1011-6.
32. 2/prostaglandin endoperoxide receptor antagonist. J Cardiovasc Pharmacol. 1993;21:441-7.
33. Enzan K, Shouji K, Inaba H, et al. Inhibition of pulmonary hypertensive response after antigen challenge. Shock. 1995;4:294-7.
34. 2 causes retarded clearance of aggregated protein in glomeruli of nephritic mice. Eur J Pharmacol. 2001;413:271-9.
35. Yokota M, Uchibori S, Hayashi H, et al. Azulene derivatives as TXA2/PGH2 receptor antagonists-II: synthesis and biological activity of 6-mono- and 6-dihydroxylated- isopropylazulenes. Bioorg Med Chem. 1996;4:575-91.
36. Mehta J, Nichols WW, Goldman R. Prostacyclin release following endoperoxide analogue infusion in the intact dog. Am J Physiol. 1984;246(2 part 2):R205-10.
37. Evers AS, Murphree S, Saffitz JE, et al. Effects of endogenously produced leukotrienes, thromboxane, and prostaglandins on coronary vascular resistance in rabbit myocardial infarction. J Clin Invest. 1985;75:992-9.
38. 2 release during coronary occlusion and reperfusion by 2-phenylaminoadenosine (CV-1808) in anesthetized dogs. J Cardiovasc Pharmacol. 1984;6:442-8.
39. 2 and thromboxane A in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation. 2001;104:2210-5.
40. Bertolino F, Valentin JP, Patoiseau JF, et al. Evidence for partial agonist properties of daltroban (BM 13,505) at TP receptors in the anaesthetized open-chest rat. Naunyn Schmiedebergs Arch Pharmacol. 1997;356:462-6.
41. Bolli R, Patel BS, Jeroudi MO, et al. Demonstration of free radical generation in 'stunned' myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tert-butyl nitrone. J Clin Invest. 1988;82:476-85.
42. Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart: evidence for a free radical mechanism of reperfusion injury. J Biol Chem. 1988;263:1353-7.
43. Powell SR, Tortolani AJ. Recent advances in the role of reactive oxygen intermediates in ischemic injury. I. Evidence demonstrating presence of reactive oxygen intermediates; II. Role of metals in site-specific formation of radicals. J Surg Res. 1992;53:417-29.
44. Merrill GF, Goldberg E. Antioxidant properties of acetaminophen and cardioprotection. Basic Res Cardiol 2001;96:423-30.